Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases. As a leading orphan endocrine disease company, we create distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following potentially first-in-class product candidates: Livoletide (AZP-531) for the treatment of Prader-Willi syndrome; Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia; MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause. Source
No articles found.
Biomerica, Inc. is a global biomedical company that develops, manufactures and mar...
Biomerica, Inc. is a global biomedical company ...
Tonix is a clinical-stage biopharmaceutical company focused on discovering and dev...
Tonix is a clinical-stage biopharmaceutical com...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisens...
NeuBase Therapeutics, Inc. is developing its mo...
Theravance Biopharma is a diversified biopharmaceutical company with the core purp...
Theravance Biopharma is a diversified biopharma...
Our mission is to improve the lives of patients by developing novel, best-in-class...
Our mission is to improve the lives of patients...
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
Join the National Investor Network and get the latest information with your interests in mind.